Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK board conflict of interest

Executive Summary

Case Western Reserve University School of Medicine Dean Ralph Horwitz will not join GlaxoSmithKline's board as a non-executive director due to a potential conflict of interest concerning a decongestant component of a withdrawn SmithKline Beecham product. Horwitz was an investigator in a study linking phenylpropanolamine to hemorrhagic stroke. Over-the-counter medicines containing PPA were withdrawn from the market in 2000, prompting lawsuits against GSK and other drug makers (1"The Pink Sheet" Nov. 13, 2005, p. 25)...

You may also be interested in...

Knoll Meridia Discount Program Uses Advance PCS Pharmacy Card

Advance PCS will manage Knoll Pharmaceutical's discount program for its weight-loss product Meridia.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

Shuttered US Supplement Firm Meets Recall Deadline, But Schumer Says FDA Late Cleaning Up Industry

While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts